

# MARKET REPORT



## EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

## Summary

RSV is a common cause of pediatric respiratory infections, and virtually all children will have been infected by the virus by the age of two years. Also, RSV is recognized as an important cause of respiratory illness in adults. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, although about 1% of cases develop serious lower respiratory complications requiring hospitalization. In older adults, RSV can result in significant morbidity and mortality, and is easily transmissible in living facilities, such as nursing homes. Children under the age of two years and adults over 64 years of age, with certain health conditions, are most at risk for severe RSV infections, and it is therefore recommended that they receive prophylactic treatment.

In each of the 7MM, GlobalData epidemiologists determined that the prophylactic RSV population in 2014, which includes the preterm infant (less than 37 weeks gestational age) population that survived to 2 years of age, the population of infants with neonatal chronic lung disease (CLD), the population of children with congenital respiratory or neuromuscular diseases that compromise respiratory function, the population of children with hemodynamically significant congenital heart disease, and the population of third-trimester pregnant women, was highest for the US, followed by the 5EU (France, Germany, Italy, Spain, and UK) and Japan. This trend was also seen in the hospitalized RSV population, where the US had the highest number of confirmed and estimated RSV hospitalized cases in 2014, followed by the 5EU and Japan.

GlobalData epidemiologists provide a well-rounded, evidence-based historical trend analysis and population forecast for the RSV prophylactic and hospitalized populations. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Each population, including the hospitalized population, was also segmented by ages (0 years, 1 year, and 2 years) and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized market in the 7MM. Furthermore, the forecast is based on an in-depth analysis of a comprehensive set of factors that may impact the RSV prophylactic and hospitalized populations. These factors include trends in population changes, births, preterm births, infant mortality, and the disease incidence, prevalence, and mortality.

## Scope

- The Respiratory Syncytial Virus (RSV) Infection EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the for the pediatric population hospitalized due to RSV infection (hospitalized population), in addition to the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population) in these markets.
- The RSV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

## Reasons to buy

<https://www.bioportfolio.co.uk/product/17996>  
[bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) to order

The RSV EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global RSV market.
- Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RSV prophylactics and therapeutics in each of the markets covered.

## Additional Details

**Publisher** : Global Data

**Reference** : GDHCER111-15

**Number of Pages** : 69

**Report Format** : PDF

**Publisher Information** :



**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

- 1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 72 Introduction 82.1 Catalyst 82.2 Upcoming Reports 83 Epidemiology 93.1 Disease Background 93.2 Risk Factors and Comorbidities 103.3 Global Trends 123.3.1 Preterm Infants and Children Born Preterm and Survived to Two Years of Age 133.3.2 Infants with Neonatal CLD 133.3.3 Children with Hemodynamically Significant Congenital Heart Disease 143.3.4 Children with Congenital Respiratory or Neuromuscular Diseases That Compromise Respiratory Function 153.3.5 Third-Trimester Pregnant Women 153.3.6 Hospitalizations for RSV Infection 163.4 Forecast Methodology 173.4.1 Sources Used 233.4.2 Sources Not Used 313.4.3 Forecast Assumptions and Methods 323.5 Epidemiological Forecast for RSV Infection (2014-2024) 413.5.1 Risk Groups for Severe RSV Infection in Children Less than Two Years 413.5.2 Preterm Births 473.5.3 Neonatal CLD 483.5.4 Third-Trimester Pregnant Women 493.5.5 RSV Hospitalizations in Children 503.6 Discussion 523.6.1 Epidemiological Forecast Insight 523.6.2 Limitations of the Analysis 543.6.3 Strengths of the Analysis 544 Appendix 564.1 Bibliography 564.2 About the Authors 644.2.1 Epidemiologists 644.2.2 Reviewers 644.2.3 Global Director of Therapy Analysis and Epidemiology 644.2.4 Global Head of Healthcare 664.3 About GlobalData 674.4 About EpiCast 674.5 Disclaimer 68

# List Of Tables in EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

## 1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Severe RSV Infection 11

Table 2: 7MM, Sources Used to Determine the Preterm Infant Population, 2014 18

Table 3: 7MM, Sources Used to Determine the Incidence of Neonatal CLD, 2014 19

Table 4: 7MM, Sources Used to Determine the Incidence of Hemodynamically Significant Heart Disease in Children, 2014 20

Table 5: 7MM, Sources Used to Determine the Diagnosed Prevalence of Congenital Respiratory and Neuromuscular Diseases That Compromise Respiratory Function in Children, 2014 21

Table 6: 7MM, Sources Used to Determine the Third-Trimester Pregnant Women Population, 2014 22

Table 7: NICHD Neonatal CLD Severity Categorization 25

Table 8: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages  $\leq 2$  Years, N, 2014 43

Table 9: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages  $\leq 2$  Years, N, 2024 44

Table 10: 7MM, Preterm Births, Boys and Girls,  $<37$  Weeks' GA, N (Row %), 2014 48

Table 11: 7MM, Incident Cases of Neonatal CLD by Severity, Boys and Girls,  $<32$  Weeks GA, N (Row %), 2014 49

Table 12: 7MM, Third-Trimester Pregnant Women, N, 2014 and 2024 50

Table 13: 7MM, Confirmed RSV Hospitalizations in Children, Ages 0-2 Years, N, 2014 51

Table 14: 7MM, Estimated RSV Hospitalizations in Children, Ages 0-2 Years, N, 2014 51



# List Of Figures, Charts and Diagrams in EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

## 1.2 List of Figures

Figure 1: Case Flow Map for RSV Prophylactic and Therapeutic Populations 23

Figure 2: Population Estimates and Births Forecast for the US, Boys and Girls, 1997-2024 33

Figure 3: 7MM, Children Born Preterm (<37 Weeks' GA) Surviving to Ages 0-2 Years, Boys and Girls, N, 2014 and 2024 45

Figure 4: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages  $\leq 2$  Years, N, 2014 46

Figure 5: 7MM, Children at Risk for Severe RSV Infection, Boys and Girls, Ages  $\leq 2$  Years, N, 2024 47

# How to Buy...

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/17996>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$3396** | Single User Price
- \$6792** | Site License Price
- \$10187** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.